Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Article

EGFR Tyrosine Kinase Inhibitor (PD153035) Improves Glucose Tolerance and Insulin Action in High-Fat Diet–Fed Mice

  1. Patricia O. Prada1,
  2. Eduardo R. Ropelle1,
  3. Rosa H. Mourão1,
  4. Claudio T. de Souza1,
  5. Jose R. Pauli1,
  6. Dennys E. Cintra1,
  7. André Schenka2,
  8. Silvana A. Rocco3,
  9. Roberto Rittner3,
  10. Kleber G. Franchini1,
  11. José Vassallo2,
  12. Lício A. Velloso1,
  13. José B. Carvalheira1 and
  14. Mario J.A. Saad1⇑
  1. 1Department of Internal Medicine, State University of Campinas, Campinas, Brazil;
  2. 2Chemistry Institute, State University of Campinas, Campinas, Brazil;
  3. 3Department of Pathology, State University of Campinas, Campinas, Brazil.
  1. Corresponding author: Mario J.A. Saad, msaad{at}fcm.unicamp.br.
  1. P.O.P. and E.R.R. contributed equally to this article.

Diabetes 2009 Dec; 58(12): 2910-2919. https://doi.org/10.2337/db08-0506
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • FIG. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Effects of acute or chronic PD153035 administration in fed mice. (A–C, upper panels). Representative blots show the tyrosine phosphorylation of EGFR of control mice, HFD mice, and HFDPD 1 and 14 days in liver (A), muscle (B), and adipose (C). Total protein expression of EGFR (A–C, lower panels). D: Body weight. E: Epididymal fat pad weight. F: Retroperitoneal fat pad weight. G: Mesenteric fat pad weight. H: Fasting plasma glucose. I: Glucose tolerance test. J: Serum insulin during glucose tolerance test. K: Glucose disappearance rate. L: Serum FFAs. Data are presented as means ± S.E.M from six to eight mice per group. *P < 0.05 vs. control group; #P < 0.01 vs. HFD. IB, immunoblot; IP, immunoprecipitate.

  • FIG. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Effects of PD153035 administration on insulin signaling in fed mice. Representative blots show tyrosine phosphorylation of IRβ in liver (A), muscle (B), and adipose (C) of control mice, HFD mice, and HFDPD during 14 days (upper panels). Total protein expression of IRβ (A–C, lower panels). Tyrosine phosphorylation of IRS-1 in liver (D), muscle (E), and retroperitoneal (F) of control mice, HFD mice, and HFDPD 14 days (upper panels). Total protein expression of IRS1 (D–F, lower panels). Serine phosphorylation of Akt in liver (G), muscle (H), and adipose (I) of control mice, HFD mice, and HFDPD 1 and 14 days (upper panels). Total protein expression of Akt (G–I, lower panels). Data are presented as means ± SE from six to eight mice per group. *P < 0.05 control vs. HFD group; #P < 0.05 HFPD 14 days vs. HFD. IB, immunoblot.

  • FIG. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Effects of PD153035 administration on modulators of insulin signaling. Representative blots show the expression of IKKβ phosphorylation in liver (A), muscle (B), and retroperitoneal (C) of control mice, HFD mice, and HFDPD 1 and 14 days (upper panels). Total protein expression of IKKβ (A–C, lower panels). IκBα in liver (D), muscle (E), and adipose (F) of control mice, HFD mice, and HFDPD 1 and 14 days. NFκB p50 activation was determined in nuclear extracts from liver (G), muscle (H), and adipose (I) tissue by ELISA. JNK phosphorylation in liver (J), muscle (K), and adipose (L) of control mice, HFD mice, and HFDPD 1 and 14 days (upper panels). Total protein expression of JNK (J–L, lower panels). c-Jun phosphorylation in liver (M), muscle (N), and adipose (O) of control mice, HFD mice, and HFDPD 1 and 14 days. IRS1 serine 307 phosphorylation in liver (P), muscle (Q), and adipose (R) of control mice, HFD mice, and HFPD 1 and 14 days (upper panels). Total protein expression of IRS-1 (P–R, lower panels). Data are presented as means ± SE from six mice per group, *P < 0.05 vs. control group and #P < 0.05 vs. HFD. IB, immunoblot.

  • FIG. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    Effects of PD153035 on adipocyte morphology and activation and migration of macrophages in adipocyte tissue. A: Histological sections of retroperitoneal fat pads from control, HFD, and HFDPD after 1 or 14 days, 50-μm scale bar for all pictures. B: Quantification of adipocyte size. About 100 cells were measured in each group, and the average adipocyte was calculated. C: Representative immunohistochemical staining of WAT using the specific macrophage marker F4/80+. D: F4/80-positive cells (+cells/total cells) of all above groups. Data are presented as means ± SE from six mice per group, *P < 0.05 vs. control group and #P < 0.05 vs. HFD. E: Bar graph indicates the number of THP1 cells that migrate from the top to the bottom level of the Boyden blindwell chamber stimulated or not with chemotatic agent RANTES. *P < 0.05 vs. DMSO alone; #P < 0.05 vs. DMSO/RANTES. Values represent the average of five different assays. (A high-quality color digital representation of this figure is available in the online issue.)

  • FIG. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    Effect of PD153035 on tissue protein levels of TNF-α, IL-6, and iNOS and arginase activity in adipocytes and SVF from retroperitoneal adipose tissue. Representative blots show the tissue levels of TNF-α, IL-6, iNOS, EGRF tyrosine phosphorylation, EGRF, Caveolin, and Cd68 protein expression in adipocytes (A–D) and TNF-α, IL-6, iNOS, EGRF tyrosine phosphorylation, EGRF, Cd68, and actin protein expression in the SVF (F–J). K: Arginase activity of adipocytes and SVF from control mice, HFD mice, and HFDPD 1 and 14 days. Serum levels of adiponectin (L), TNF-α (M), leptin (N), and IL-6 (O) and MCP-1 (P), MCP-2 (Q), and MCP-3 (R) protein expression were obtained using ELISA assay. Data are presented as means ± SE of six to eight mice per group. *P < 0.05 vs. control group; #P < 0.05 vs. HFD group.

PreviousNext
Back to top

In this Issue

December 2009, 58(12)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
EGFR Tyrosine Kinase Inhibitor (PD153035) Improves Glucose Tolerance and Insulin Action in High-Fat Diet–Fed Mice
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
EGFR Tyrosine Kinase Inhibitor (PD153035) Improves Glucose Tolerance and Insulin Action in High-Fat Diet–Fed Mice
Patricia O. Prada, Eduardo R. Ropelle, Rosa H. Mourão, Claudio T. de Souza, Jose R. Pauli, Dennys E. Cintra, André Schenka, Silvana A. Rocco, Roberto Rittner, Kleber G. Franchini, José Vassallo, Lício A. Velloso, José B. Carvalheira, Mario J.A. Saad
Diabetes Dec 2009, 58 (12) 2910-2919; DOI: 10.2337/db08-0506

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

EGFR Tyrosine Kinase Inhibitor (PD153035) Improves Glucose Tolerance and Insulin Action in High-Fat Diet–Fed Mice
Patricia O. Prada, Eduardo R. Ropelle, Rosa H. Mourão, Claudio T. de Souza, Jose R. Pauli, Dennys E. Cintra, André Schenka, Silvana A. Rocco, Roberto Rittner, Kleber G. Franchini, José Vassallo, Lício A. Velloso, José B. Carvalheira, Mario J.A. Saad
Diabetes Dec 2009, 58 (12) 2910-2919; DOI: 10.2337/db08-0506
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Original Article

  • An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes
  • Loss of Prohibitin Induces Mitochondrial Damages Altering β-Cell Function and Survival and Is Responsible for Gradual Diabetes Development
  • Cbl-b Is a Critical Regulator of Macrophage Activation Associated With Obesity-Induced Insulin Resistance in Mice
Show more Original Article

Pharmacology and Therapeutics

  • SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial
  • Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench
  • Anti-Insulin Receptor Antibodies Improve Hyperglycemia in a Mouse Model of Human Insulin Receptoropathy
Show more Pharmacology and Therapeutics

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.